<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594422</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-0003</org_study_id>
    <nct_id>NCT03594422</nct_id>
  </id_info>
  <brief_title>A Study of HQP1351 in Patients With GIST or Other Solid Tumors</brief_title>
  <official_title>A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HealthQuest Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2&#xD;
      Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or&#xD;
      Other Solid Tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients&#xD;
      with GIST or other solid tumors. The secondary objective is to assess the safety,&#xD;
      tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or&#xD;
      Other Solid Tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized at 1:1:1 ratio into the three dose cohorts: 30 mg QOD, 40 mg QOD and 50 mg QOD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>30 days after the last dose of HQP1351</time_frame>
    <description>Patients with HQP1351 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1.</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1.</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activities of HQP1351</measure>
    <time_frame>3-6 months</time_frame>
    <description>Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>HQP1351 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg QOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HQP1351 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg QOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HQP1351 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg QOD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HQP1351</intervention_name>
    <description>HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.</description>
    <arm_group_label>HQP1351 30mg</arm_group_label>
    <arm_group_label>HQP1351 40mg</arm_group_label>
    <arm_group_label>HQP1351 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or not pregnant or lactating women, age≥18 years.&#xD;
&#xD;
          2. Advanced and/or metastatic GIST or other solid tumor subjects that are confirmed by&#xD;
             histology and/or cytology. Among them, GIST patients are required primary imatinib&#xD;
             resistance (PDGFRA D842V mutation or NF1 mutation) or failed to previous treatment&#xD;
             with imatinib or imatinib and at least one other TKI.&#xD;
&#xD;
          3. ECOG≤ 2.&#xD;
&#xD;
          4. Estimated survival at least 3 months.&#xD;
&#xD;
          5. Adequate hematologic and bone marrow functions.&#xD;
&#xD;
          6. Adequate renal and liver function.&#xD;
&#xD;
          7. Heart function index:&#xD;
&#xD;
               -  Troponin(I/T) ≤ Upper Limit of Normal;&#xD;
&#xD;
               -  Ejection fraction &gt;40%;&#xD;
&#xD;
               -  QTc interval ≤ 450 ms in male or ≤ 470 ms in female.&#xD;
&#xD;
          8. Negative serum pregnancy test (for women of childbearing potential) documented within&#xD;
             the 24-hour prior to the first dose of investigational product.&#xD;
&#xD;
          9. Willing to use contraception by a method that is deemed effective by the investigator&#xD;
             by Subject and their partners throughout the treatment period and for at least 30 days&#xD;
             following the last dose of study drug.&#xD;
&#xD;
         10. Ability to understand and willingness to sign a written informed consent form (the&#xD;
             consent form must be signed by the subject prior to any study-specific procedures).&#xD;
&#xD;
         11. Willing and ability to comply with study procedures and follow-up examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any anti-cancer chemotherapy, biological agent treatment (e.g. Monoclonal&#xD;
             antibody), immunotherapy (e.g. IFN) or radiotherapy with 28 days or 5 times half- time&#xD;
             before first dose of HQP1351.&#xD;
&#xD;
          2. Received any TKIs within 14 days before first dose of HQP1351.&#xD;
&#xD;
          3. Attended any clinical trials on other drugs within 14 days before first dose of&#xD;
             HQP1351.&#xD;
&#xD;
          4. Have not recovered (&gt; Grade 1 by CTCAE, v. 4.0) from AEs (except alopecia) due to&#xD;
             agents previously administered.&#xD;
&#xD;
          5. Malabsorption syndrome or other diseases that affect the absorption of oral drugs.&#xD;
&#xD;
          6. Cardiovascular diseases of clinical significance, uncontrollable or active, including&#xD;
             but not limited to: history of myocardial infarction; unstable history of angina&#xD;
             pectoris; a history of congestive heart failure or lower left ventricular ejection&#xD;
             fraction (LVEF) than normal limit within 6 months; the history of atrial arrhythmias&#xD;
             was judged by the researchers to have important clinical significance; history of&#xD;
             ventricular arrhythmias, etc.&#xD;
&#xD;
          7. Hypertension was still poorly controlled after medication treatment (SBP &gt; 140 mmHg&#xD;
             and/or DBP &gt; 90 mmHg).&#xD;
&#xD;
          8. Concurrent use any medication led to prolong QT interval.&#xD;
&#xD;
          9. Pulmonary mean arterial pressure&gt;35 mmHg by ECHO.&#xD;
&#xD;
         10. Significant severe cardiovascular conditions during previous TKI treatment.&#xD;
&#xD;
         11. Uncontrollable hypertriglyceridemia.&#xD;
&#xD;
         12. Performed major surgery (except for intravenous catheterization or bone marrow biopsy)&#xD;
             within 14 days of first dose of HQP1351.&#xD;
&#xD;
         13. Arterial thrombosis or embolism events such as cerebrovascular accident (including&#xD;
             transient ischemic attack, TIA), or venous thrombosis events or pulmonary embolism&#xD;
             within 6 months before the first dose of HQP1351 or deep vein thrombosis within 3&#xD;
             months before the first dose of HQP1351.&#xD;
&#xD;
         14. Brain metastasis.&#xD;
&#xD;
         15. Had other primary malignant tumors in the last three years (exception of the tumors&#xD;
             being cured for 5 years or more, or complete removal of non-melanoma skin cancer or&#xD;
             successful treatment of carcinoma in situ, or the controlled prostate cancer).&#xD;
&#xD;
         16. Had active, symptomatic infections (including known infections of HIV, viral hepatitis&#xD;
             (A, B, or C)). If there is no history of infection, screening is not required.&#xD;
&#xD;
         17. Subjects who are known to be allergic to pharmaceutical ingredients or their analogs.&#xD;
&#xD;
         18. Pregnancy or lactation, or expect to be pregnant during the study period.&#xD;
&#xD;
         19. According to the judgment of the investigator or sponsor, any symptoms or disease of&#xD;
             the subject may jeopardize the safety or safety assessment of the subject.&#xD;
&#xD;
         20. Any other condition or circumstance of that would, in the opinion of the investigator,&#xD;
             make the patient unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifan Zhai, M.D., Ph.D.</last_name>
    <phone>+86-20-28069260</phone>
    <email>yzhai@ascentagepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun-Yat Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Professor</last_name>
      <phone>+86-20-87343468</phone>
      <email>ruihxu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiwei Zhou, Professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Li, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangbin Wang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaixiong Tao, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA general hospital, Beijing, China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wu, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Zhou, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

